Study M1117
Study name | Tkachev A 2023 |
Title | Lipid alteration signature in the blood plasma of individuals with schizophrenia, depression, and bipolar disorder |
Overall design | The aim of this study was to identify significant blood plasma lipidome alterations in individuals with schizophrenia, major depressive disorder (MDD), and bipolar disorder. This was a multicohort case-control diagnostic analysis involving plasma samples from psychiatric patients and control individuals. For the Chinese cohort, 222 MDD patients (MDD group) and 153 healthy control subjects (control group) were recruited. For the Russian cohort, 34 MDD patients (MDD group) and 138 healthy control subjects (control group) were recruited. Plasma lipid intensities were measured using liquid-chromatography coupled with untargeted mass spectrometry. |
Study Type | Type1; |
Data available | Unavailable |
Organism | Human; |
Categories of depression | Depressive disorder; Depression; Depression; |
Criteria for depression | DSM-IV or ICD-10 diagnosed MDD |
Sample size | 547 |
Tissue | Peripheral; Blood; Plasma; |
Platform | MS-based; LC-MS: Waters Acquity UPLC system (Waters, Manchester, UK) with Q Exactive orbitrap mass spectrometer (Thermo Fisher Scientific, USA); |
PMID | |
DOI | |
Citation | Tkachev A, Stekolshchikova E, Vanyushkina A, et al. Lipid alteration signature in the blood plasma of individuals with schizophrenia, depression, and bipolar disorder. JAMA Psychiatry. 2023 Mar 1;80(3):250-259. |
Metabolite | Bilirubin; LysoPC(16:0); LysoPC(18:0); L-Carnitine; LysoPC(18:1); LysoPC(20:1); Carnitine C10:1; Carnitine C12:0; Carnitine C14:2; Carnitine C14:1; Carnitine C14:0; Carnitine C16:2; Carnitine C16:0; PC(32:1); PC(36:5); PC(38:4); PC(38:5); PC(O-36:4); PC(O-38:5); LysoPC(15:0/0:0); LysoPE(18:2); LysoPE(18:1); LysoPC(22:4); LysoPE(20:3); LysoPE(22:5); PE(34:2); PE(36:4); LysoPC(16:1/0:0); LysoPE(16:1); LysoPE(16:0); PC(32:0); TG(45:2); PE(38:5); LysoPC(20:4); LysoPC(14:0); PC(30:0); PC(36:1); PC(40:5); PE(P-40:4); PE(P-36:4); PE(36:5); PE(P-36:2); PE(36:1); LysoPC(20:0/0:0); PE(P-38:6); PE(36:3); LysoPE(20:4); PE(34:1); PE(36:2); PE(P-40:6); PC(34:1); PC(40:4); PE(P-38:4); PE(P-40:7); PE(P-40:5); PC(O-42:5); DG(34:1); DG(36:1); PC(33:1); PC(38:2); TG(40:0); TG(42:0); TG(42:1); TG(44:0); TG(44:1); TG(44:2); TG(46:0); TG(46:1); TG(46:2); TG(46:3); TG(47:1); TG(47:2); TG(48:0); TG(48:1); TG(48:3); TG(48:4); TG(49:0); TG(49:1); TG(49:2); TG(49:3); TG(50:0); TG(50:1); TG(50:2); TG(50:3); TG(51:1); TG(51:2); TG(52:1); TG(52:2); TG(52:3); TG(54:2); TG(54:3); TG(56:4); TG(58:3); LysoPC(O-18:0); LysoPC(22:5); Carnitine C10:0; LysoPC(17:0/0:0); LysoPC(19:0); LysoPC(19:1); LysoPE(20:5); SM(d43:2); DG(36:2); LysoPE(18:3); LysoPC(O-22:1); LysoPC(20:2); TG(48:5); TG(46:4); LysoPC(P-18:1); TG(51:3); PC(35:2); PE(38:3); Carnitine C18:0; Carnitine C18:1; DG(36:4); |
